Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy' [Seeking Alpha]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Seeking Alpha
Early data show that lasme-cel reached impressive ORRs in Phase 1, and CLLS should give us a pivotal Phase 2 readout expected in 2026. CLLS also has partnerships with big pharma companies like Allogene, Servier, Iovance, and AstraZeneca that should provide added optionality. CLLS's valuation multiples also seem relatively cheap versus its peers, while having a manageable runway. In my view, CLLS is a great speculative “Buy” based on its clinical potential with lasme-cel, cheap valuation, and R&D partnerships. humonia/iStock via Getty Images Cellectis S.A. ( CLLS ) is a biotech that leverages its Transcription Activator-Like Effector Nucleases (TALEN) and PulseAgile electroporation to develop allogeneic CAR-T medications. This way, CLLS targets conditions with high-unmet needs or heavily pretreated patients in B-cell malignancies. The company has This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the comp
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca (AZN) At the Center of Serious Analyst Attention [Yahoo! Finance]Yahoo! Finance
- US is best place to invest, says boss of British drugs giant [Yahoo! Finance]Yahoo! Finance
- Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In? [Yahoo! Finance]Yahoo! Finance
- AstraZeneca (NASDAQ:AZN) had its "buy" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat
- AstraZeneca (NASDAQ:AZN) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
AZN
Sec Filings
- 12/4/25 - Form 6-K
- 12/1/25 - Form 6-K
- 12/1/25 - Form 6-K
- AZN's page on the SEC website